Literature DB >> 33403597

PACAP and NAP: Effect of Two Functionally Related Peptides in Diabetic Retinopathy.

Agata Grazia D'Amico1, Grazia Maugeri2, Giuseppe Musumeci2, Dora Reglodi3, Velia D'Agata4.   

Abstract

Pituitary adenylate cyclase-activating polypeptide (PACAP) is a peptide involved in physio-pathological processes of the eye. It exerts multiple effects directly through activation of its related receptors and indirectly through increases in the synthesis of activity-dependent neuroprotective protein (ADNP). To study the role of ADNP and protect against ADNP deficiencies, a small peptide called NAP was synthetized. It includes an eight amino acid active site sequence of ADNP. In this review, we summarize the knowledge regarding the neuroprotective function played by PACAP and NAP in retinal tissue and provide an overview of the correlation between PACAP and ADNP in the context of diabetic retinopathy.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC part of Springer Nature.

Entities:  

Keywords:  ADNP; Diabetic retinopathy; Hyperglycemia; NAP; PACAP

Mesh：

Substances：

Year:  2021        PMID： 33403597     DOI： 10.1007/s12031-020-01769-4

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN： 0895-8696            Impact factor:   3.444


  107 in total

1.  Complete sequence of a novel protein containing a femtomolar-activity-dependent neuroprotective peptide.

Authors:  M Bassan; R Zamostiano; A Davidson; A Pinhasov; E Giladi; O Perl; H Bassan; C Blat; G Gibney; G Glazner; D E Brenneman; I Gozes
Journal:  J Neurochem       Date:  1999-03       Impact factor: 5.372

2.  Effects of PACAP in UV-A radiation-induced retinal degeneration models in rats.

Authors:  Tamas Atlasz; Krisztina Szabadfi; Peter Kiss; Zsuzsanna Marton; Monika Griecs; Levente Hamza; Valeria Gaal; Zsolt Biro; Andrea Tamas; Gabor Hild; Miklos Nyitrai; Gabor Toth; Dora Reglodi; Robert Gabriel
Journal:  J Mol Neurosci       Date:  2010-06-03       Impact factor: 3.444

3.  Identification of VIP/PACAP receptors on rat astrocytes using antisense oligodeoxynucleotides.

Authors:  O Ashur-Fabian; E Giladi; D E Brenneman; I Gozes
Journal:  J Mol Neurosci       Date:  1997-12       Impact factor: 3.444

4.  Pituitary adenylate cyclase-activating polypeptide (PACAP) can act as determinant of the tyrosine hydroxylase phenotype of dopaminergic cells during retina development.

Authors:  Juliana Carrazzoni Borba; Isabela Pereira Henze; Mariana Souza Silveira; Regina Célia Cussa Kubrusly; Patrícia Franca Gardino; Maria Christina Fialho de Mello; Jan Nora Hokoç; Fernando Garcia de Mello
Journal:  Brain Res Dev Brain Res       Date:  2005-05-12

5.  A peptide derived from activity-dependent neuroprotective protein (ADNP) ameliorates injury response in closed head injury in mice.

Authors:  L Beni-Adani; I Gozes; Y Cohen; Y Assaf; R A Steingart; D E Brenneman; O Eizenberg; V Trembolver; E Shohami
Journal:  J Pharmacol Exp Ther       Date:  2001-01       Impact factor: 4.030

6.  Pituitary adenylate cyclase activating polypeptide is protective in bilateral carotid occlusion-induced retinal lesion in rats.

Authors:  Tamás Atlasz; Norbert Babai; Péter Kiss; Dóra Reglodi; Andrea Tamás; Krisztina Szabadfi; Gábor Tóth; Orsolya Hegyi; Andrea Lubics; Róbert Gábriel
Journal:  Gen Comp Endocrinol       Date:  2006-12-31       Impact factor: 2.822

7.  Effects of pituitary adenylate cyclase activating polypeptide and its fragments on retinal degeneration induced by neonatal monosodium glutamate treatment.

Authors:  Tamás Atlasz; Krisztina Szabadfi; Dóra Reglodi; Péter Kiss; Andrea Tamás; Gábor Tóth; Alexandra Molnár; Klaudia Szabó; Róbert Gábriel
Journal:  Ann N Y Acad Sci       Date:  2009-04       Impact factor: 5.691

Review 8.  Perspectives on pituitary adenylate cyclase activating polypeptide (PACAP) in the neuroendocrine, endocrine, and nervous systems.

Authors:  A Arimura
Journal:  Jpn J Physiol       Date:  1998-10

Review 9.  Pituitary adenylate cyclase activating polypeptide (PACAP) and its receptors: neuroendocrine and endocrine interaction.

Authors:  A Arimura; S Shioda
Journal:  Front Neuroendocrinol       Date:  1995-01       Impact factor: 8.606

10.  PACAP-mediated neuroprotection of neurochemically identified cell types in MSG-induced retinal degeneration.

Authors:  Tamas Atlasz; Krisztina Szabadfi; Peter Kiss; Norbert Babai; Zsombor Koszegi; Andrea Tamas; Dora Reglodi; Robert Gabriel
Journal:  J Mol Neurosci       Date:  2008-04-17       Impact factor: 3.444
View more
  3 in total

1.  Distribution of PACAP and PAC1 Receptor in the Human Eye.

Authors:  Evelin Patko; Edina Szabo; Denes Toth; Tamas Tornoczky; Inez Bosnyak; Alexandra Vaczy; Tamas Atlasz; Dora Reglodi
Journal:  J Mol Neurosci       Date:  2022-03-07       Impact factor: 3.444

2.  Vineland Adaptive Behavior Scale in a Cohort of Four ADNP Syndrome Patients Implicates Age-Dependent Developmental Delays with Increased Impact of Activities of Daily Living.

Authors:  Joseph Levine; Fahed Hakim; R Frank Kooy; Illana Gozes
Journal:  J Mol Neurosci       Date:  2022-08-03       Impact factor: 2.866

3.  The Protective Effects of Endogenous PACAP in Oxygen-Induced Retinopathy.

Authors:  Timea Kvarik; Dora Reglodi; Dora Werling; Alexandra Vaczy; Petra Kovari; Edina Szabo; Krisztina Kovacs; Hitoshi Hashimoto; Tibor Ertl; Judit Gyarmati; Tamas Atlasz
Journal:  J Mol Neurosci       Date:  2021-04-24       Impact factor: 3.444
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.